# CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients

> **NCT05061654** · PHASE4 · WITHDRAWN · sponsor: **Hamad Medical Corporation**

## Conditions studied

- Neutropenia, Febrile
- Hematologic Cancer

## Interventions

- **DRUG:** Ceftolozane-tazobactam IV

## Key facts

- **NCT ID:** NCT05061654
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-08
- **Primary completion:** 2024-01
- **Final completion:** 2024-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative constraints
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061654, "CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05061654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*